EPIDYOLEX

This brand name is authorized in Australia, Austria, Croatia, Estonia, Finland, France, Ireland, Italy, Lithuania, Poland, Romania, UK.

Active ingredients

The drug EPIDYOLEX contains one active pharmaceutical ingredient (API):

1	Cannabidiol UNII 19GBJ60SN5 - CANNABIDIOL
	Cannabidiol is indicated for the treatment of seizures associated with Lennox‑Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older.
	Read more about Cannabidiol

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
EPIDYOLEX Oral solution	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N03AX24		N Nervous system → N03 Antiepileptics → N03A Antiepileptics → N03AX Other antiepileptics
Discover more medicines within N03AX24

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	12467E
EE	Ravimiamet	1801460, 1849866
FI	Lääkealan turvallisuus- ja kehittämiskeskus	400959
FR	Base de données publique des médicaments	61680130
GB	Medicines & Healthcare Products Regulatory Agency	380299
IE	Health Products Regulatory Authority	89117
IT	Agenzia del Farmaco	048251019
LT	Valstybinė vaistų kontrolės tarnyba	1088498
PL	Rejestru Produktów Leczniczych	100417524
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69656001